Introduction: Type 2 diabetes mellitus (T2DM)
INTRODUCTION
Diabetes is an increasing problem in both developed and developing countries, and is a leading risk factor for vascular disease [1] .
Recent estimates indicate that the prevalence of type 2 diabetes mellitus (T2DM) in the UK is around 4.3% [2] . Rising obesity and the demographic shift to an older population suggest that this prevalence will increase.
The treatment of T2DM comprises a combination of lifestyle changes and drug therapy. Care pathways for people with T2DM aim to address a decline in beta cell function typically via escalation from diet and exercise regimens to oral therapies and eventually insulin [3] . Oral antidiabetic drugs (OADs) are the mainstay of therapy for many T2DM patients, but many do not achieve the optimal reductions in weight, blood pressure or glycated hemoglobin (HbA1c), and might benefit from additional therapy. Consensus algorithms advocate the addition of a second OAD or basal insulin to metformin monotherapy, based on their glucose-lowering properties [4, 5] . While international organizations recommend a range of options for second-line therapy [5] , the National Institute for Health and Care Excellence (NICE) recommends addition of a sulphonylurea (SU) as the preferred second-line option [4] .
Recommended treatment algorithms that are based on the attainment of blood glucose targets may not account for changes in other cardiovascular risk factors in patients escalating from first-line monotherapy. This study aims to describe the unmet clinical need, defined as failure to reduce weight or meet targets for systolic blood pressure (SBP), total cholesterol (TC) or HbA1c levels in T2DM patients taking commonly prescribed OADs.
METHODS
A retrospective cohort study was conducted to summarize patient characteristics (numbers on treatment, age, sex, concomitant lipid or blood pressure-lowering therapy) to estimate changes in the following cardiovascular risk factors:
HbA1c, weight, SBP, and TC; and to estimate proportions of patients achieving outcome targets (i.e., HbA1c \7.5%) for each OAD therapy cohort: mono, dual, triple, and insulin therapy.
Data Source
This study used retrospective cohort data extracted from The Health Improvement Network (THIN) database [6] . THIN currently contains the records of 9.1 million patients (3.4 million active patients) collected from *500 general practices across the UK. THIN is a suitable data source for this study, which focuses on an unselected group of diabetic patients from the general population, rather than a specialist study group. This study was granted ethical approval from the Scientific Review Committee (SRC) (Reference 11-023, July 04, 2011).
Study Population
The study cohort consists of men and women with a diagnosis of T2DM recorded during the study period: 01/01/2005-31/12/2009. The index date was defined as the date of the first diagnosis recorded within the study period. Patients aged \25 years at index date and/or with steroid-induced or gestational diabetes were excluded. Patients were required to have at least 365 days of follow-up pre-and post-first OAD prescription, at least one reading of SBP, weight and HbA1c in 365 days prior to the first prescription date and at least two readings in 365 days following the first prescription date.
The study focused on conventional therapies of the time and as such patients taking novel agents (e.g., DPP-4 inhibitors) were excluded. 
Study Variables and Analysis

RESULTS
Results by Therapy Cohort
A total of 36,942 T2DM patients treated with one or more pharmacological agent in UK general practice were identified in the THIN dataset, with an average age of [60. The majority used a single OAD (monotherapy; n = 23,626), with progressively fewer subjects using two (dual therapy; n = 7,230) and three OADs (triple therapy; n = 1,612). There were a further 4,474 insulin users. There was an apparent positive association between lipidlowering and blood pressure pharmacological therapies, and progression from a single to multiple OADs (Table 1) .
All OAD cohorts were associated with an increase in mean HbA1c prior to OAD initiation (monotherapy) or escalation (dual and triple therapy), followed by an observed decline in mean HbA1c post-initiation/ escalation (Table 1 ; Fig. 1 ). Insulin users had the highest starting HbA1c levels (mean ± SD: 9.78 ± 1.94). Among noninsulin users, HbA1c levels prior to OAD progression were highest in the triple therapy cohort (8.71 ± 1.19), followed by dual therapy (8.48 ± 1.28) and monotherapy (8.03 ± 1.24). Across all therapy cohorts, statistically significant (P \ 0.05) changes in HbA1c between -0.93 and -1.47 were observed in the period following therapy progression.
Mean HbA1c levels observed in each OAD cohort before and after the initiation/escalation of therapy, plotted against the HbA1c profile predicted using results of the UK Prospective Diabetes Study (UKPDS) can be seen in Fig. 2 With regard to the risk factors SBP and TC, the monotherapy cohort experienced an average reduction of -1.96 ± 0.10 in SBP (P\0.001) and -0.52 ± 0.02 in TC (P\0.001). Dual therapy subjects and insulin users were associated with a decrease in TC and increase in SBP, while the converse was observed in subjects adding a third OAD. Attainment of SBP and TC targets was low, despite the use of blood pressure and lipid-lowering medications in the majority of patients. Overall, the proportion of subjects that attained targets across all four risk factors (HbA1c, weight, SBP, TC) was highest in the dual therapy cohort (6%), followed by triple therapy (5%) and monotherapy (3%). Target attainment among insulin users was 3% on average, similar to the monotherapy group (Table 1) .
Results by OAD Combination Within
Therapy Cohort
The majority of monotherapy subjects used metformin (89.59%) followed by an SU (glibenclamide, gliclazide, glimepiride, glipizide or tolbutamide; 9.77%), a thiazolidinedione (TZD; 0.58%) and other (-1.18 ± 0.06, P\0.001); all OAD groups were associated with a reduction in HbA1c. Though other monotherapy users gained weight, the initiation of metformin was associated with a reduction in weight of -1.98 ± 0.33, P\0.001 (SDC Table 1 ). SBP generally decreased for each of the OADs, except for SU which was associated with an increase of 0.41 ± 0.68, P = 0.541. A reduction in TC was observed for each of the main OAD types (P\0.001, except for TZD users). No more than 3% of patients attained all four targets in each OAD group. Rates of achievement were consistently lowest for the weight target (7-18%). The TZD group had the highest achievement of individual outcomes, with the exception of TC: 39% for HbA1c, 18% for weight, 54% for SBP, and 26% for TC.
Following monotherapy, the addition of SU to metformin accounted for 55.34% of all dual therapy subjects (SDC Table 2 ). SU added to metformin was associated with a reduction in HbA1c of -1.13 ± 0.04 (P\0.001) and weight gain of 1.28 ± 0.60 (P = 0.033); SBP increased (0.76 ± 0.42, P = 0.066), and TC was reduced by -0.21 ± 0.03 (P\0.001).
Following the addition of SU, 6% of metformin subjects achieved all four outcomes targets, compared to 7% in SU users who added metformin, and 7% in metformin users who added TZD.
In subjects progressing to a third OAD, results were consistent with respect to the direction of change for each outcome for each of the OAD types analyzed (SDC Table 3 ). Table 4 ). HbA1c and TC levels consistently fell among insulin users (P \ 0.001), while weight (P \ 0.05) and SBP (P \ 0.01) increased in all the three OAD groups. Similar proportions of patients achieved target attainment in each OAD/ insulin group (1-3%).
Results by Age
Subgroup analyses of patients above and below 70 years of age did not suggest that levels of target attainment were lower in older patients (SDC Table 5 ). With the exception of SBP in patients receiving more than one OAD, observed attainment rates of individual and combined targets were not lower in the higher age group.
DISCUSSION
Unmet clinical need may be broadly defined as a ''medical need that is not addressed adequately by an existing therapy'' [10] . In the context of pharmacological management of T2DM, this definition relates to treatments that do not improve or adequately control risk factors. Previous studies have demonstrated delays in treatment intensification in UK clinical practice despite poor glycemic control [11] . In this study, the cardiovascular risk factors, weight, SBP, and TC, were considered in addition to glycemic control, the predominant measure of success of pharmacotherapy in this setting [10] . HbA1c levels prior to therapy initiation/ escalation were higher with the addition of each OAD, and were higher again in insulin users. This might reflect a decline in beta cell function that is associated with the natural progression of T2DM, and hence the need for more intensive pharmacological management [3] . A pattern of increased or decreased starting levels from single to multiple OAD therapies was not observed for weight. However, for both SBP and TC, levels prior to initiation of monotherapy were higher than levels prior to escalation to a second and third OAD. Together, these findings indicate that in UK general practice, therapy escalation in the management of T2DM is triggered by the need for better glycemic control (as evidenced by higher starting levels prior to change). It may be inferred that SBP and TC, conversely, do not drive the timing of therapy escalation, as evidenced by the lower starting levels for these outcomes in the multiple OAD cohorts, though they may influence the choice of additional OAD at therapy escalation.
The 2012 quality outcomes framework (QoF) results suggested that attainment levels of HbA1c targets (B7%) in England and Wales were approaching 70%. Attainment of blood pressure and cholesterol targets were *71% and 82%, respectively [12, 13] . Measures such as QoF paint a picture of successful T2DM management with respect to the control of cardiovascular risk factors and the satisfaction of related targets; however, results presented herein suggest that this is not the case for the many patients requiring therapy escalation in clinical practice.
Of the four targets evaluated, lowest attainment levels were observed for weight.
Some glucose-lowering therapies are associated with weight gain, which may contribute to these observations. Weight change was included in this study despite this link due to its importance as a recognized cardiovascular risk factor, associated with excess mortality risk [14] and negative impact on quality of life [15] .
To support economic evaluation, many T2DM disease models utilize results from UKPDS, including predicting the expected trajectory of HbA1c levels [9] . However, realworld observations suggest that the HbA1c profiles of patients undergoing treatment escalation do not conform to this average predicted trajectory, and additional OADs may be added sooner than is predicted. A possible explanation for this may be that there exists a group of slow progressing patients, whose HbA1c is well controlled, bringing the average On this limitation, the aim of this study was to statistically describe the observed data; as such, statistical techniques to (potentially) address such bias were not employed at the data extraction or analysis stage, though such techniques cannot fully account for the inherent limitations of datasets such as THIN.
It is considered, however, that the value of these analyses outweighs this limitation [19] . In line with the audit-style approach of the study, the significance of missing records among routinely collected data was not investigated.
This study was a cross-sectional analysis of patient cohorts defined by the number of and timing of pharmacotherapies used in the management of T2DM. It was not possible to map the trajectory of individual patients as they moved from single to multiple OADs and to insulin therapy.
Treatment goals are highly individualized in practice. Though clinicians may take a more cautious approach to the management of elderly patients, results did not suggest that target attainment was lower in patients aged [70 years. While lower HbA1c targets of 6.5% or 7% may be appropriate for some patients, 
